v3.26.3
Segment Reporting (Details)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
USD ($)
Jun. 30, 2026
USD ($)
Mar. 31, 2026
USD ($)
Sep. 30, 2025
USD ($)
Jun. 30, 2025
USD ($)
Mar. 31, 2025
USD ($)
Sep. 30, 2026
USD ($)
segment
Sep. 30, 2025
USD ($)
Segment Reporting [Abstract]                
Number of operating segments | segment             1  
Number of reportable segments | segment             1  
Segment Reporting [Line Items]                
Total revenue $ 1,951     $ 1,752     $ 4,973 $ 4,606
Total research and development 12,500     11,149     34,445 29,081
General and administrative 7,204     8,228     22,563 21,446
Total operating expenses 19,704     19,377     57,008 50,527
Loss from operations (17,753)     (17,625)     (52,035) (45,921)
Other income (expense):                
Interest Income (649)     (207)     (1,174) (778)
Interest Expense 3,090     1,314     8,886 3,856
Loss on extinguishment of debt 0     0     (2,383) 0
Change in fair value of derivative liability 16,562     0     14,671 0
Other (expense) income, net 34     (1,319)     (194) (1,141)
Total other (expense) income 14,155     (2,426)     4,382 (4,219)
Net loss (3,598) $ (24,877) $ (19,177) (20,051) $ (14,739) $ (15,350) (47,653) (50,140)
Collaborative Arrangements                
Segment Reporting [Line Items]                
Total revenue 1,951     1,752     4,973 4,606
Total research and development 200     800     1,500 1,900
Reportable Segment                
Segment Reporting [Line Items]                
Research and development personnel costs 5,284     4,353     16,036 12,454
Facilities and other support costs 837     864     2,646 2,665
Other 303     726     1,639 1,870
Total research and development 12,500     11,149     34,445 29,081
General and administrative 7,204     8,228     22,563 21,446
Total operating expenses 19,704     19,377     57,008 50,527
Loss from operations (17,753)     (17,625)     (52,035) (45,921)
Other income (expense):                
Interest Income (649)     (207)     (1,174) (778)
Interest Expense 3,090     1,314     8,886 3,856
Loss on extinguishment of debt 0     0     (2,383) 0
Change in fair value of derivative liability 16,562     0     14,671 0
Other (expense) income, net 34     (1,319)     (194) (1,141)
Total other (expense) income 14,155     (2,426)     4,382 (4,219)
Net loss (3,598)     (20,051)     (47,653) (50,140)
Reportable Segment | OCU400                
Segment Reporting [Line Items]                
Research and development expense (excluding acquired in process cost) 2,986     3,616     6,502 7,463
Reportable Segment | OCU410 and OCU410ST                
Segment Reporting [Line Items]                
Research and development expense (excluding acquired in process cost) 2,834     1,373     6,799 3,675
Reportable Segment | NeoCart                
Segment Reporting [Line Items]                
Research and development expense (excluding acquired in process cost) 61     19     279 25
Reportable Segment | COVAXIN                
Segment Reporting [Line Items]                
Research and development expense (excluding acquired in process cost) 3     0     13 0
Reportable Segment | Inhaled mucosal vaccine platform                
Segment Reporting [Line Items]                
Research and development expense (excluding acquired in process cost) 145     67     224 399
Reportable Segment | OCU200                
Segment Reporting [Line Items]                
Research and development expense (excluding acquired in process cost) 47     131     307 530
Reportable Segment | Collaborative Arrangements                
Segment Reporting [Line Items]                
Total revenue $ 1,951     $ 1,752     $ 4,973 $ 4,606